Celltrion Healthcare Co., Ltd.
High uncertainty:The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
-90.3% vs price
Base Case (Median)
-88.3% vs price
Bull Case (75th pct.)
-79.9% vs price
◇ = Current price | |Bear |Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $7025.83 | -90.7% | High (40%) |
| PE Comparable | $6100.04 | -92.0% | Medium (25%) |
| Growth Trajectory DCF | $7654.49 | -89.9% | Medium (20%) |
| Graham Number | $8885.12 | -88.3% | Medium (40%) |
| EV/EBITDA | $14519.99 | -80.9% | Medium (20%) |
| EV/FCF | $16013.06 | -78.9% | Medium (20%) |
| Earnings Power Value | $16258.13 | -78.6% | Medium (50%) |
Based on 7 out of 8 methods, 091990.KQ appears overvalued at the current price of $75900.00. The base case fair value of $8885.12 implies 88.3% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.